Rapport Therapeutics (RAPP) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital

1. 01make milestone, royalty, interest or other payments due under any future financing or other arrangements with third parties
2. 02We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts
3. 03the extent to which we acquire or invest in business, products and technologies
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates
5. 05The obligations from our license agreement with Janssen may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations

Risks Related to Our Business

1. 06varying interpretations of data by the FDA, EMA, MHRA or other comparable regulatory authorities
2. 07The successful development of pharmaceutical products involves a lengthy and expensive process and is highly uncertain
3. 08the proprietary rights of others and their competing products and technologies that may prevent our product candidates from being commercialized
4. 09increased legal and accounting compliance costs
5. 10Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy and data security. For example, the European Union’s General Data Protection Regulation (“EU GDPR”) and the United Kingdom’s GDPR (“UK GDPR”) impose strict requirements for processing personal data
6. 11If we were to experience a material cyber-attack, cybersecurity incident, breach, compromise, or other interruption that causes interruptions in our operations, it could result in a material disruption of our product development programs

Risks Related to the Discovery and Development of Our Current or Future Product Candidates

1. 12The regulatory approval processes of the FDA, EMA, MHRA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
2. 13the approval policies or regulations of the FDA, EMA, MHRA or other comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
3. 14The FDA, EMA, MHRA or comparable regulatory authorities may disagree with our regulatory plan for our product candidates
4. 15We are dependent on a third party having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that were previously conducted for our product candidates
5. 16If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates
6. 17We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
7. 18the potential for approval policies or regulations of the FDA, EMA, MHRA or other comparable regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval
8. 19later-stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted
9. 20Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained
10. 21Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates
11. 22Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data
12. 23If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business and results of operations may be harmed
13. 24the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities
14. 25We have concentrated our research and development efforts on the treatment of disorders of the nervous system, a field that faces certain challenges in drug development
15. 26We may be subject to additional risks because we intend to evaluate our product candidates in combination with the standard of care for the indications that we are pursuing
16. 27We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with our protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion
17. 28the risk that patients enrolled in our clinical trials will drop out of the trials before completion
18. 29Even if any of our product candidates receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable
19. 30If we fail to discover, develop and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired
20. 31a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors
21. 32If we are unsuccessful in identifying and developing additional product candidates, either through internal development or licensing or acquisition from third parties, our potential for growth and achieving our strategic objectives may be impaired
22. 33In most cases, we do not currently plan to run head-to-head clinical trials evaluating our product candidates against the current standards of care, which may make it more challenging for our product candidates to compete against the current standards of care due to the lack of head-to-head clinical trial data
23. 34If we are unable to develop our sales, marketing and distribution capability on our own or through collaborations with marketing partners, we will not be successful in commercializing our product candidates
24. 35unforeseen costs and expenses associated with creating an independent sales and marketing organization

Risks Related to Employee Matters and Managing Growth

1. 36We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
2. 37Our ability to develop product candidates, leverage our RAP technology platform and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel

Risks Related to Our Dependence on Third Parties

1. 38We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed
2. 39results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions
3. 40the possible misappropriation of our proprietary information, including our trade secrets and know-how
4. 41The FDA, EMA, MHRA or other comparable regulatory authorities require manufacturers to register manufacturing facilities, and also inspect these facilities to confirm compliance with cGMPs
5. 42We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans
6. 43If we enter into collaborations with third parties for the development and commercialization of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations
7. 44collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates
8. 45If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed
9. 46Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay

Risks Related to Government Regulation

1. 47Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
2. 48injunctions or the imposition of civil or criminal penalties
3. 49review and process our regulatory submissions, which could have a material adverse effect on our business. Further, government shutdowns could impact our ability to access the public markets and obtain additional capital in the future
4. 50Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably
5. 51neither experimental nor investigational
6. 52Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations
7. 53Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
8. 54Off-label use or misuse of our product candidates may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits
9. 55EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU Member States
10. 56We are subject to export and import controls, economic sanctions, and anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business
11. 57If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business
12. 58provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials

Risks Related to Our Intellectual Property

1. 59We depend on in-licensed intellectual property. If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business
2. 60If our efforts to protect the proprietary nature of the intellectual property related to our product candidates are not adequate, we may not be able to compete effectively in our market
3. 61whether we or our licensors will need to initiate or defend litigation or administrative proceedings which may be costly regardless of whether we or our licensors win or lose
4. 62Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
5. 63Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO
6. 64Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
7. 65We may not be able to protect our intellectual property rights throughout the world
8. 66If we do not obtain patent term extension for any of our current product candidates, our business may be materially harmed
9. 67Third parties may initiate legal proceedings alleging that we are infringing or otherwise misappropriating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
10. 68we may be forced to try to redesign our product candidates or processes so they do not infringe third-party intellectual property rights, an undertaking which may not be possible or which may require substantial monetary expenditures and time
11. 69Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming
12. 70Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
13. 71We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
14. 72If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
15. 73We may be subject to claims that we wrongfully hired an employee from a competitor or that our employees have misappropriated intellectual property, including trade secrets of their former employers
16. 74If our trademarks and trade names are not adequately protected then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
17. 75European patents and patent applications could be challenged in the recently created Unified Patent Court for the European Union

Risks Related to Ownership of Our Common Stock

1. 76An active trading market for our common stock may not be sustained
2. 77The price of our common stock may be volatile, which could result in substantial losses for our stockholders
3. 78other events or factors, many of which are beyond our control
4. 79Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations
5. 80the level of demand for our product candidates, if approved, which may vary significantly over time
6. 81If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
7. 82Our executive officers, directors, principal stockholders and their respective affiliates own a significant percentage of our common stock and have the ability to exert significant control over matters subject to stockholder approval
8. 83Our common stock price could decline as a result of sales of a large number of shares of common stock or the perception that these sales could occur, which might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate
9. 84Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders
10. 85We do not currently intend to pay dividends on our common stock and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation of the value of our common stock
11. 86Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management
12. 87require the approval of not less than two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our third amended and restated certificate of incorporation or amended and restated bylaws
13. 88Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees
14. 89We may not be able to continue to satisfy the listing requirements of The Nasdaq Stock Market (“Nasdaq”)

Other General Risks

1. 90Unfavorable global economic conditions, political instability and geopolitical events could adversely affect our business, financial condition, stock price, and results of operations
2. 91We, or the third parties upon whom we depend, may be adversely affected by natural disasters, public health crises or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
3. 92We are eligible to be treated as an “emerging growth company” and a “smaller reporting company” and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
4. 93exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved
5. 94We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices
6. 95Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
7. 96Our ability to use our net operating loss carryforwards and other tax attributes may be limited
8. 97Changes in tax law could adversely affect our business and financial condition
9. 98Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
10. 99the inability to commercialize any products that we may develop
11. 100We may become involved in litigation that could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages